Current topics in melanoma Journal Article
| Authors: | Wolchok, J. D.; Saenger, Y. M. |
| Article Title: | Current topics in melanoma |
| Abstract: | PURPOSE OF REVIEW: New approaches to melanoma are emerging. This review summarizes developments over the past 12 months. RECENT FINDINGS: Surgical, chemotherapeutic, immunologic and targeted therapies for melanoma are evolving. Sentinel lymph node sampling is now accepted as the standard of care for patients with intermediate thickness primary melanomas. Temozolomide continues to be widely used as part of combination therapy, and recent evidence suggests that a combination of temozolomide and interferon-α may be superior to temozolomide alone. Meanwhile, temozolomide and thalidomide carries unacceptable thrombosis risk. In the area of immunotherapy, anti-CTLA-4 continues to show promise, but special attention must be paid to gastrointestinal toxicity. Interferon-α, in addition, has shown efficacy in the neoadjuvant setting with inflammatory infiltrates demonstrated in tumors. A better understanding of the complex genetic regulation of melanoma cell growth is emerging and this is expected to lead to the development of novel targeted therapies. SUMMARY: Research is producing a more complete understanding of melanoma genetics and immune regulation. These are beginning to produce therapeutics that are impacting clinical practice. © 2007 Lippincott Williams & Wilkins, Inc. |
| Keywords: | signal transduction; mitogen activated protein kinase; protein kinase b; treatment response; cancer surgery; unclassified drug; gene mutation; fludarabine; thalidomide; clinical trial; fatigue; review; sorafenib; raf protein; cancer combination chemotherapy; drug efficacy; monotherapy; side effect; antineoplastic agents; drug targeting; alpha interferon; paclitaxel; adjuvant therapy; cancer adjuvant therapy; chemotherapy; temozolomide; drug megadose; sentinel lymph node biopsy; clinical practice; t lymphocyte; carboplatin; dacarbazine; interleukin 2; ipilimumab; protein p16; ticilimumab; cancer immunotherapy; melanoma; gene expression profiling; blood toxicity; libido disorder; combination chemotherapy; cyclophosphamide; steroid; deep vein thrombosis; immunoregulation; standard; cancer genetics; chromosome aberration; drug induced headache; gastrointestinal toxicity; immunotherapy; diagnostic value; thrombosis; medical research; phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase; brain metastasis; adoptive transfer; gene control; autoimmunity; targeted therapy; ras protein; inflammatory infiltrate; cytotoxic t lymphocyte antigen 4; autoimmune disease; wnt protein; amnesia; b raf kinase; cytopenia; mitogen activated protein kinase kinase; immunosuppressive agents; hypophysitis; immunoconjugates; peginterferon; hypophysis; infliximab; t lymphocyte antibody; cp 675206; cytotoxic t lymphocyte antibody 4; protein bnip3; autoimmune hypophysitis |
| Journal Title: | Current Opinion in Oncology |
| Volume: | 19 |
| Issue: | 2 |
| ISSN: | 1040-8746 |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 2007-03-01 |
| Start Page: | 116 |
| End Page: | 120 |
| Language: | English |
| DOI: | 10.1097/CCO.0b013e32801497c6 |
| PUBMED: | 17272983 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 11" - "Export Date: 17 November 2011" - "CODEN: CUOOE" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work